• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Vaginal and intramuscular progesterone reduce high-risk singleton preterm birth

byAlice WangandTeddy Guo
April 12, 2021
in Obstetrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Systematic review of RCTs demonstrates reduced rate of early preterm birth (<34 weeks) for high-risk (previous spontaneous preterm birth, short cervix) singleton pregnancies with vaginal progesterone and intramuscular 17-hydroxyprogesterone caproate (17-OHPC).

2. Efficacy of vaginal progesterone and 17-OHPC may be more effective for women with short cervices. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Preterm birth remains a major global cause of infant death and adverse health complications. Progesterone supplementation has been shown to reduce the risk of preterm birth and stands as the current clinical recommendation. This systematic review of international randomized control trials (RCTs) aimed to compare the efficacy of vaginal progesterone, intramuscular 17-OHPC, oral progesterone, and control for preventing preterm birth in high-risk pregnancies and reducing adverse maternal fetal outcomes. After employing rigorous screening of available studies and standardization of data inclusion, the primary outcome for this study was preterm birth (<34 weeks’ gestation); associated neonatal and maternal complications were assessed as well. According to study results, vaginal progesterone and 17-OHPC reduced the risk of preterm birth in high-risk pregnancies compared to control in singleton pregnancies. This risk reduction was most significant in high risk pregnancies due to short cervix. This study was limited by the availability and heterogeneity of data in the included trials, compromising the ability to assess the impact of oral progesterone and progesterone treatment on maternal and fetal outcomes.

Click to read the study in The Lancet

Relevant Reading: Prevention of Preterm Parturition 

In-Depth [systematic review and meta-analysis]: This study aggregated participant-level data from 31 randomized control trials and included 11644 participants to assess the impact of exogenous progesterone (vaginal progesterone, intramuscular 17-OHPC, and oral progesterone) on preterm delivery for high-risk pregnancies. High-risk was defined as previous preterm birth or short cervix (<25mm). The outcome preterm birth was subcategorized to preterm birth (delivery <37 weeks), early preterm birth (delivery <34 weeks), and mid-trimester birth (delivery <28 weeks); singleton and multigestational pregnancies were analyzed separately. Various adverse neonatal events and adverse maternal outcomes were assessed in tandem.

RELATED REPORTS

Immediate postpartum opioid administration not associated with adverse infant outcomes

Patients with early pregnancy loss less likely to receive active management in the emergency department

The 2 Minute Medicine Podcast Episode 11

When compared with control in singleton pregnancies, both vaginal progesterone and 17-OHPC reduced risk of preterm delivery <34 weeks (vaginal progesterone relative risk [RR] 0.78, 95% CI 0.68-0.90: 17-OHPC RR 0.83, 95% CI 0.68-1.01). However, this benefit was not observed in multigestational pregnancies (vaginal progesterone RR 1.01, 95% CI 0.84-1.20; 17-OHPC RR 1.04, 95% CI 0.92-1.18). Additionally, reduced risks of low birthweight (<2500 g), very low birthweight (<1500 g), and respiratory distress syndrome were seen with both vaginal progesterone and 17-OHPC. There was insufficient data from oral progesterone trials to reach meaningful conclusions. Regarding adverse neonatal and maternal outcomes, exogenous progesterone offered tempered benefits for reducing risk of neonatal severe necrotizing enterocolitis and severe retinopathy of prematurity in singleton pregnancies. The effects of exogenous progesterone on risk of maternal complications was unclear due to heterogeneity in collected data in singleton trials. Vaginal progesterone and IM 17-OHPC injections can cause adverse reactions and discomfort, thus engaging the mother in shared decision making is critical.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: 17-hydroxyprogesterone caproate (17-OHPC)childbirthobstetricsoral progesteronepregnancypregnancy complicationspreterm birthpreterm birthspreterm deliveryprogesteronevaginal progesterone
Previous Post

#VisualAbstract: Local excision margins greater than 1 cm and receipt of radiotherapy are associated with improved overall survival in Merkel cell carcinoma

Next Post

Clinical practice algorithm reduces endotracheal aspirate cultures in PICU

RelatedReports

Nivolumab may be effective in platinum-resistant ovarian cancer
Obstetrics

Immediate postpartum opioid administration not associated with adverse infant outcomes

March 28, 2023
American Academy of Pediatrics recommends standards for adverse event disclosures
Chronic Disease

Patients with early pregnancy loss less likely to receive active management in the emergency department

March 23, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 11

March 23, 2023
Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia
Obstetrics

Similar perinatal outcomes observed amongst conception via natural and assisted reproductive means

March 20, 2023
Next Post
Teixobactin appears to avoid bacteria resistance [PreClinical]

Clinical practice algorithm reduces endotracheal aspirate cultures in PICU

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

Sex and race‐ethnic disparities in door‐to‐CT time in acute ischemic stroke found in Florida Stroke Registry

#VisualAbstract: Local excision margins greater than 1 cm and receipt of radiotherapy are associated with improved overall survival in Merkel cell carcinoma

#VisualAbstract: Major postoperative complications are associated with worse long-term survival in patients undergoing esophagectomy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options